Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that inhibits HIV integrase. In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background anti...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 359; no. 4; pp. 339 - 354
Main Authors: Steigbigel, Roy T, Cooper, David A, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R, Lennox, Jeffrey L, Gatell, Jose M, Rockstroh, Jurgen K, Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Zhao, Jing, Chen, Joshua, Ryan, Desmond M, Rhodes, Rand R, Killar, John A, Gilde, Lucinda R, Strohmaier, Kim M, Meibohm, Anne R, Miller, Michael D, Hazuda, Daria J, Nessly, Michael L, DiNubile, Mark J, Isaacs, Robin D, Nguyen, Bach-Yen, Teppler, Hedy
Format: Journal Article
Language:English
Published: Boston, MA Massachusetts Medical Society 24.07.2008
Subjects:
Adolescent
Adult
Aged
Antiretroviral drugs
Biological and medical sciences
CD4 Lymphocyte Count
Clinical trials
Double-Blind Method
Drug dosages
Drug Resistance, Viral
Drug therapy
Drug Therapy, Combination
Female
Follow-Up Studies
General aspects
HIV
HIV Infections - drug therapy
HIV Integrase Inhibitors - adverse effects
HIV Integrase Inhibitors - therapeutic use
HIV Integrase Inhibitors/adverse effects/therapeutic use
HIV-1 - genetics
HIV-1 - isolation & purification
HIV-1/genetics/isolation & purification
Human health sciences
Human immunodeficiency virus
Human viral diseases
Humans
Immunologie & maladie infectieuse
Immunology & infectious disease
Infectious diseases
Logistic Models
Male
Medical sciences
Middle Aged
Neoplasms - etiology
Organic Chemicals - adverse effects
Organic Chemicals - therapeutic use
Organic Chemicals/adverse effects/therapeutic use
Pyrrolidinones
Raltegravir Potassium
RNA, Viral - blood
Sciences de la santé humaine
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Immunopathology
Antiretroviral agent
HIV-1 virus
Retroviridae
AIDS
Immune deficiency
Lentivirus
Infection
Virus
Medicine
Resistance
Integrase inhibitor
Treatment
Viral disease
Antiviral
Human immunodeficiency virus
Raltegravir
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that inhibits HIV integrase. In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). Highly active antiretroviral therapy is the standard of care for patients with advanced human immunodeficiency virus (HIV) infection. 1 Combination regimens have resulted in improved survival, decreased morbidity, and cost-effective care for patients with a CD4 count of less than 350 per cubic millimeter. 2 – 8 However, viral suppression cannot always be achieved or sustained with standard treatments because of the development of viral resistance, toxic effects of drugs, or lack of adherence. 9 – 18 The majority of HIV-infected patients in whom highly active antiretroviral therapy fails have resistant viral quasispecies. 12 – 15 , 19 , 20 Cross-resistance to agents within a drug class may exhaust . . .
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Feature-3
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
scopus-id:2-s2.0-47949120697
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa0708975